Cure for cancer? Israeli scientists claim to be on brink of development
But at least one expert in the U.S. has questioned the potential cure’s legitimacy and said it’s more likely just another claim on a list of “irresponsible and ultimately cruel false promises” for cancer patients.
The company, Accelerated Evolution Biotechnologies Ltd. (AEBi), has described its treatment, MuTaTo, as comparable to a cancer antibiotic that uses a multipronged approach similar to the treatment given to HIV patients. The Israeli team told The Jerusalem Post that this treatment relies on a combination of several peptides for each cancer cell, reportedly eliminating the chances of evasion through mutation.
“More likely, this claim is yet another in a long line of spurious, irresponsible and ultimately cruel false promises for cancer patients.”
“We believe we will offer in a year’s time a complete cure for cancer,” Dan Aridor, of AEBi, told the news outlet.
The company’s CEO, Dr. Ilan Morad, said MuTaTo also works to target cancer stem cells, eliminating the chances of recurrence, with Aridor claiming that it will be effective from “Day 1” and cause “no or minimal side effects at a much lower cost than most other treatments.”
“Our solution will be both generic and personal,” Aridor said.
But Dr. Ben Neel, director of Perlmutter Cancer Center at NYU Langone Health, is skeptical, telling Fox News via email: “Of course, curing cancer is the goal of everyone who comes to work every day at a cancer center — and if this company does, in fact, cure cancer, they will have my congratulations and thanks. But cancer is multiple diseases, and it is highly unlikely that this company has found a ‘cure’ for cancer, anymore than there is a single cure for infections.”
The treatment has not been tested in humans yet, although Aridor said it has shown success in mice and is nearing the clinical trial stage.
Said Neel, “More likely, this claim is yet another in a long line of spurious, irresponsible and ultimately cruel false promises for cancer patients.”